NCT04502225 Effect of Raised Head of the Bed on Lying Blood Pressure in Autonomic Failure
| NCT ID | NCT04502225 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Vanderbilt University Medical Center |
| Condition | Supine Hypertension |
| Study Type | INTERVENTIONAL |
| Enrollment | 44 participants |
| Start Date | 2020-08-21 |
| Primary Completion | 2027-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 44 participants in total. It began in 2020-08-21 with a primary completion date of 2027-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Many persons with autonomic failure often have high blood pressure when lying down (supine hypertension). This study is exploring the impact of decreased venous return to the heart (achieved by raising the head of the bed) to lessen supine blood pressure. If decreased venous return to the heart is effective at lowering supine blood pressure, these approaches may be utilized to treat supine hypertension non-pharmacologically. Raising the head of the bed decreases the amount of blood returning to the heart due to the effects of gravity. In this case, the decreased blood return to the heart may decrease blood pressure.
Eligibility Criteria
Inclusion Criteria: * Patients with autonomic failure and with supine hypertension from all races * Males and females, between 18 to 85 years Exclusion Criteria: * All medical students * Pregnant women * High-risk patients (for example: heart failure, symptomatic coronary artery disease, liver impairment, history of stroke or myocardial infarction) * History of serious allergies or asthma.
Contact & Investigator
Italo Biaggioni, MD
PRINCIPAL INVESTIGATOR
Vanderbilt University Medical Center
Frequently Asked Questions
Who can join the NCT04502225 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Supine Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04502225 currently recruiting?
Yes, NCT04502225 is actively recruiting participants. Contact the research team at bonnie.black@vumc.org for enrollment information.
Where is the NCT04502225 trial being conducted?
This trial is being conducted at Nashville, United States.
Who is sponsoring the NCT04502225 clinical trial?
NCT04502225 is sponsored by Vanderbilt University Medical Center. The principal investigator is Italo Biaggioni, MD at Vanderbilt University Medical Center. The trial plans to enroll 44 participants.